Use or purchase of prescribed medication; Bodily functions, vital signs, symptoms, or measurements of health information; Diagnoses or diagnostic testing, treatment, or medication; Genetic data; Precise location information that could reasonably indicate a resident's attempt to acquire or receive health...
Use or purchase of prescribed medication; Bodily functions, vital signs, symptoms, or measurements of health information; Diagnoses or diagnostic testing, treatment, or medication; Genetic data; Precise location information that could reasonably indicate a resident's attempt to acquire or receive health...
medication (which could have been an inhaled GCS) with periodic use of breakthrough medication for at least three months prior to Visit 1; and (c) basal FEV1of ≧50% of predicted and reversibility of ≧15% at 15±5 minutes after a standard dose of inhaled bronchodilator for patients ...
Finally, I'd like to provide an update on the TROPION-Lung01 filing. Following discussions with the FDA, we've submitted a biologics license application for approval in later-line EGFR-mutated non-small cell lung cancer. With the encouragement of the FDA, we've also applied for breakthrough...
(or inspiration) ensures optimal delivery of aerosol medication to the target region in the respiratory tract, with minimal losses due to deposition in the mouth and pharynx. For multiple dose inhalers, the triggering and dispensing mechanisms must be reset after each actuation to enable a ...
mutations identified in exon 20 have been linked to resistance to EGFR TKIsNon-Small Cell Lung Cancer: Biologic and Therapeutic Considerations for Personalized Management Taofeek K. Owonikoko, MD, PhD What is the role and application of molecular profiling in the management of NSCLC? It is essenti...
Severe asthma, inadequately controlled despite background controller medication, MD & HD ICS + LABA ± chronic OCS Age 18-75 years 162 • Arm 1: Fasenra 30mg Q4W s.c. 28-week (adults) Global trial - two countries • Primary endpoint: functionality, reli...
Abstract: The invention provides novel substituted cyclopentane compounds, their use as medicaments, compositions containing them and processes for their preparation. Inventors: Guile, Simon (Leicestershire, GB) Martin, Barrie (Leicestershire, GB) Application Number: 11/008895 ...
The present invention relates to a new compound of formula I as a free base or a pharmaceutically acceptable salt thereof, a process for the preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said compound in therapy.Inventors...
HMG-CoA reductase inhibitors are the most widely used prescription medication for the treatment of hypercholesterolaemia. By inhibiting the rate-controlling step in cholesterol biosynthesis, these agents effectively lower the plasma concentrations of atherogenic particles containing cholesterol such as low-den...